Coya Therapeutics Inc (COYA)$4.81
Market Cap: 107.21 MCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Coya Therapeutics Inc (COYA).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
-5.6x
EV/FCF, N/A FCF yield
Quality
-49.3%
ROIC, -135.2% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 8.5x current ratio
Superinvestors
1
Top: David Einhorn (0.3%)
Strengths to research
- Debt/equity looks manageable at 0.0x.
Watchouts
- Free cash flow margin is negative at -135.2%.
Annual data: 5 periods
Quarterly data: 16 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for COYA.
Grade F
2
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| COYA Target | Coya Therapeutics Inc | $107.2M | -3.8x | -5.6x | -49.3% | N/A | -135.2% | N/A | N/A | N/A |
| CGEN | Compugen Ltd | $128.1M | 7.4x | 1.2x | 34.4% | 105.2% | 43.1% | 87.3% | -2.8x | N/A |
| CRBU | Caribou Biosciences Inc. | $79.9M | -1.3x | -0.6x | -121.2% | -2.0% | -1006.8% | N/A | N/A | N/A |
| GUTS | Fractyl Health Inc | $79.8M | -0.5x | 0.0x | -1490.3% | N/A | N/A | N/A | N/A | N/A |
| IVVD | Invivyd Inc. | $69.0M | -3.7x | 2.7x | -21.7% | N/A | -109.1% | N/A | N/A | N/A |
| DMAC | DiaMedica Therapeutics Inc. | $171.4M | N/A | -5.4x | -58.4% | N/A | N/A | N/A | N/A | N/A |
| INBX | Inhibrx | $178.5M | -11.2x | -0.4x | -1752.2% | N/A | -9986.5% | N/A | N/A | N/A |
| GANX | Gain Therapeutics Inc. | $56.4M | -2.9x | -1.9x | -106.3% | N/A | N/A | N/A | N/A | N/A |
| PEPG | Pepgen Inc | $47.1M | -0.7x | 0.2x | -60.8% | N/A | N/A | N/A | N/A | N/A |
Financial Charts
No financial data available for COYA (annual).
1 superinvestors own COYA
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| David Einhorn Greenlight Capital | 2,335,540 | $9M | 0.29% | 0.0% |